Driving Better
Decisions

Driving Better
Decisions
Driving Better
Decisions

Leveraging Our QuAD³ Platform for Clinical Development and Novel Drug Discovery

Our proprietary QuAD³ platform allows us to define novel biological insights from our deep phenotypic and genomic patient cohorts. Comparing primary tumor with metastatic drivers across the cohorts allows us to identify mechanisms driving disease progression from the primary tumor to cancer relapse and metastasis. These insights provide a deep understanding of resistance mechanisms, enabling patient enrichment and the clinical development of our innovative therapeutic programs.

We used this causal inference approach in our recent publication, “Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort.”

Our QuAD³ Platform

Multi-omic datasets

Our QuAD³ Platform allows for the analysis of multiple data types to yield novel phenotypic and clinical-genomic insights.

Ensemble AI approach
to generate outputs

We leverage multiple algorithms to classify novel patterns and biological pathways linked to causal dependency.

Patient Enrichment

Use biomarker phenotype insights to identify favorable phenotypes sensitive to treatment.

Our multi-omic insights provide a richer understanding of the foundational drivers of therapy-induced resistance. We believe this allows us to optimize our patient enrichment strategy for our differentiated pipeline of novel clinical molecules.